Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

Darazam (COVIFERON Interferon beta-1a)
 
NCT04343768
RCTinterferonstandard of careCOVID-19 severe or criticallysome concern
20/20 suggested
  • suggested 1.4-fold increase in clinical improvement,clinical improvement (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
Darazam (COVIFERON Interferon beta-1b)
 
NCT04343768
RCTIFN beta-1bstandard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive
    Kalil (ACTT-3)
     
    NCT04492475
    RCTIFN beta-1aplaceboCOVID-19 severe or criticallysome concern
    487/482 inconclusive
    • inconclusive 1 % decrease in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    Rahmani
     
    IRCT20100228003449N2
    RCTIFN beta-1bstandard of careCOVID-19 severe or criticallysome concern
    40/40 conclusif
    • demonstrated 2.4-fold increase in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    1 study excluded by filtering options (1 RCT / 0 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).